At a Glance
- Companies: BD (Becton, Dickinson); Ypsomed AG
- Location: Le Pont‑de‑Claix, France/Burgdorf, Switzerland
- Headline figures: 5.5mL glass prefillable syringe; mid‑2026 feasibility samples
- Focus area: High‑volume, high‑viscosity biologics self‑injection
- Next steps: Expand YpsoMate 5.5 platform integration
What happened?
BD and Ypsomed expanded their partnership to develop a 5.5mL version of BD’s Neopak XtraFlow glass prefillable syringe, fully compatible with Ypsomed’s YpsoMate 5.5 autoinjector platform for large‑volume subcutaneous self‑injections. Syringe samples for feasibility studies are expected mid‑2026, with Ypsomed expanding the YpsoMate platform concurrently.
Why does it matter?
High‑dose biologics (>1mL, high viscosity up to 70cP) in oncology, autoimmune, rare diseases and metabolic disorders require patient‑friendly self‑injection systems with optimised flow and reduced injection time. The collaboration addresses rising dosing volumes/viscosities, building on prior 2.25mL success.
Who’s behind it?
BD leads in drug delivery syringes; Ypsomed specialises in autoinjectors with ergonomic two‑step activation. Proven partners since Neopak/YpsoMate 2.25 launch.
How was it achieved?
BD’s XtraFlow maximises flow efficiency; Ypsomed adapts YpsoMate 5.5 for compatibility, undergoing comprehensive testing to accelerate pharma timelines.
What’s next?
Mid‑2026 samples enable pharma feasibility; successful integration supports commercial combination products for high‑dose therapies.
What are people saying?
BD’s Patrick Jeukenne: “Direct response to growing demand for patient‑friendly high‑dose solutions.” Ypsomed’s Ulrike Bauer: “Expanding subcutaneous design space for high‑dose/volume therapies.”